Yumab GmbH

YUMAB Company profile The German biotech company YUMAB was founded in 2012 as spin-off the University of Braunschweig. In little more than five years, YUMAB (a phonetic play on “HUMAB”, which stands for “human monoclonal antibody and in which the “Y” symbolizes the well-known antibody structure) has become a global player in human monoclonal antibody (mAb) development, and drives the general trend in the immunotherapy space toward the use of fully human mAbs for therapeutic applications. The YUMAB® antibody platform provides rapid, reliable and robust development of “state-of-the-art” and “next-generation” fully human antibodies. The technologies base on more than 28 years of continuous research and development of our founders, who are well recognized scientific experts in the field of recombinant antibody technologies and who have an outstanding track-record in academic and industrial research. YUMAB provides optimized antibody development solutions for: i) discovery & development of novel, fully human antibodies, ii) antibody engineering & humanization, and iii) personalized & custom libraries Key features of the YUMAB® platform are: i) world’s best, naturally derived, universal, human antibody libraries (>10e11) ii) powerful in vitro selection technologies including on-cells-selection for difficult targets iii) large scale screening platforms iv) comprehensive portfolio of antibody engineering & humanization technologies v) compatibility to all therapeutic antibody formats YUMAB provides fee for service solutions with attractive pricing and flexible license models & options as well as collaborative projects. YUMAB’s research & development unit performs internal pipeline and partnered projects ranging from the development of novel antibody therapeutics to the discovery to novel targets technologies. Our mission is to make the best human antibody technologies available for the early development to accelerate translation of research from bench to bedsite.